Brief: New Real-World Data Show Potential Of Trilaciclib To Reduce The Substantial Burden Of Myelosuppression In Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Chemotherapy
31/03/2022 21:54
March 31 (Reuters) - G1 Therapeutics Inc GTHX.O :
* NEW REAL-WORLD DATA SHOW POTENTIAL OF TRILACICLIB TO
REDUCE THE
SUBSTANTIAL BURDEN OF MYELOSUPPRESSION IN PATIENTS WITH
EXTENSIVE-STAGE SMALL-CELL LUNG CANCER TREATED WITH CHEMOTHERAPY
Source text for Eikon: ID:nGNX9tKB8K
Further company coverage: GTHX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on G1 Therapeutics
See all newsG1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney
U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify